Latest News and Press Releases

BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

New York, USA, May 01, 2025 (GLOBE NEWSWIRE) -- Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight The schizophrenia...

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Bipolar Disorder (Manic Depression)- Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an extensive...

BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pharmaceutical interventions for schizophrenia are designed to effectively treat and mitigate the symptoms associated with schizophrenia, a...

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were...

Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Online Therapy Service for Teenagers Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The online therapy service market...

KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1...

Minerva Neurosciences (Nasdaq: NERV) today reported business updates and financial results for the third quarter of 2024 ending September 30, 2024.

New York, USA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight The rise in research and development activities in...